The RareCyte® platform for next-generation analysis of circulating tumor cells

Area of Science:

• Biomedical Engineering
• Cancer Research
• Cell Biology

Background:

• Circulating tumor cells (CTCs) are crucial biomarkers in cancer patients, correlating with clinical outcomes.
• Advanced liquid biopsy technologies are needed for detailed phenotypic and molecular analysis of CTCs.

Purpose of the Study:

• To describe a novel rare cell analysis platform for comprehensive CTC collection, identification, and single-cell molecular analysis.
• To enable multi-parameter assessment of individual CTCs for enhanced cancer diagnostics.

Main Methods:

• A four-component platform integrating density-based separation, automated multiparameter fluorescence staining, image analysis, and mechanical CTC retrieval.
• Utilizes six fluorescence channels for CTC identification and investigational biomarker analysis.
• Single-cell retrieval from fixed slides is compatible with whole genome amplification for genomic analysis.

Main Results:

• The platform successfully collects and identifies CTCs.
• Enables multi-parameter assessment of individual CTCs.
• Demonstrates compatibility with genomic analysis via whole genome amplification.

Conclusions:

• The developed rare cell analysis platform offers a comprehensive solution for CTC investigation.
• This technology advances liquid biopsy by enabling detailed single-cell phenotypic and molecular characterization.
• Facilitates deeper understanding of CTC biology and clinical relevance in cancer.